New drug seeks to clear severe skin plaques
NCT ID NCT07474792
Summary
This study aims to find the best dose of an investigational drug called ORKA-002 for treating moderate-to-severe plaque psoriasis. About 160 adults with this skin condition will receive either one of three different doses of the drug or a placebo for 16 weeks. Researchers will measure how well the drug clears skin plaques and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.